About usASPENBeiGeneEHAESMONSCLCPD-1Waldenström

Phase 2 study of pamiparib in chinese patients with advanced ovarian cancer

 Back  View
Phase 2 study of pamiparib in chinese patients with advanced ovarian cancer
 POSTER   09/2020
 Download  View

For more information about this resource, please submit a medical information request.

Rating

Rate this resource

Related resources

PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
RATIONALE 307: Tislelizumab + chemo vs chemo alone in advanced squamous NSCLC (smokers vs non-smokers)
RATIONALE 307: Tislelizumab + chemo vs chemo alone in advanced squamous NSCLC (smokers vs non-smokers)
 Back